Skip to main content

Ajit K Parhi

NIH Rank #16828
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 10895937Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

NIH Funding · FY2024

Linked Award Amount
$910.2K
Full award amounts, FY2024
Award Records
1
Records listing this PI
Award-Linked Rank
#16,828
By linked amount among FY2024 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Ajit K Parhi. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2024 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2024 award records by amount

NIH award records listing Ajit K Parhi as a PI. Multi-PI records show the full award amount for context.

  • 1R44AI174351-01A1R44
    Lead optimization of a novel cyclic aryl-indole efflux pump inhibitor (EPI) series in combination with levofloxacin against Pseudomonas aeruginosa
    $910.2K
    award amount

Award organization

Organizations that administered FY2024 awards listing Ajit K Parhi as a PI.

FY2024 award administered by Taxis Pharmaceuticals, Inc. (NJ).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    Taxis Pharmaceuticals, Inc.
  2. 2024
    $500K Cumulative Funding
  3. 2025
    $1M Cumulative Funding
  4. 2025
    $2M Cumulative Funding
  5. 2025
    Entered Top 50% Nationally
    Ranked #7328